AbbVie Inc (ABBV)

neg -1.45
Today's Range: 59.18 - 60.60 | ABBV Avg Daily Volume: 8,463,900
Last Update: 06/24/16 - 4:01 PM EDT
Volume: 9,846,327
YTD Performance: 3.49%
Open: $59.26
Previous Close: $61.31
52 Week Range: $45.45 - $71.60
Oustanding Shares: 1,617,358,607
Market Cap: 97,672,286,277
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 8 8 9
Moderate Buy 0 1 1 1
Hold 6 3 3 3
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 0
Mean Rec. 2.14 1.81 1.81 1.50
Latest Dividend: 0.57
Latest Dividend Yield: 3.78%
Dividend Ex-Date: 07/13/16
Price Earnings Ratio: 18.14
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
18.14 18.10 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
8.78% -12.44% 43.85%
Revenue 14.50 0.20 0.07
Net Income 190.00 0.00 -0.01
EPS 185.20 -0.10 -0.02
Earnings for ABBV:
Revenue 22.86B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $1.20 $1.18 $4.77 $5.69
Number of Analysts 8 6 10 10
High Estimate $1.21 $1.24 $4.85 $5.96
Low Estimate $1.19 $1.14 $4.68 $5.35
Prior Year $1.08 $1.13 $4.29 $4.77
Growth Rate (Year over Year) 11.11% 4.72% 11.24% 19.17%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Analysts cut valuation estimates after a disappointing drug study. 
With the recent pullback in the stock price, AbbVie is an attractive buy.  
Social media chatter on Wall Street ranged from new forms of so-called 'thematic ETFs' to spiking volatility.
Jun 10, 2016 | 7:53 AM EDT
ABBV was downgraded from Outperform to Market Perform, BMO Capital said. $66 price target. Uncertainty is increasing around major growt...
Further near-term weakness to $60 looks like a good spot to go long. Use an appropriate risk level.
This is because they would buy more of the winning stocks lower.
The uptick in the small- and mid-cap space bodes well for future capital appreciation.
The market is having a quiet day in front of the long holiday weekend. However, biotech is concluding another strong week, which makes two in a row. I'm noticing some small biotechs on the move today.
Keep cash on hand and be ready for oportunities as they arise.
AbbVie and Gilead Sciences are worth accumulating in a long and deep bear market for biotech.

Columnist Conversations

.... that Monday is a total bloodbath.
I was going to publish a thought piece on Pandora and Groupon for the weekend; but it will get lost with all o...
Clorox is trading at new all time highs today with the help of a nice bump in trade.  The stock is up just ov...
Spot Gold has hurdled-- and is sustaining above-- its prior significant rally peak at $1307.40, which has the ...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.